APA

Ghofrani H., Simonneau G., D'Armini A. M., Fedullo P., Howard L. S., Jaïs X., Jenkins D. P., Jing Z., Madani M. M., Martin N., Mayer E., Papadakis K., Richard D. & Kim N. H. (20180605). Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. : The Lancet. Respiratory medicine.

Chicago

Ghofrani Hossein-Ardeschir, Simonneau Gérald, D'Armini Andrea M, Fedullo Peter, Howard Luke S, Jaïs Xavier, Jenkins David P, Jing Zhi-Cheng, Madani Michael M, Martin Nicolas, Mayer Eckhard, Papadakis Kelly, Richard Dominik and Kim Nick H. 20180605. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. : The Lancet. Respiratory medicine.

Harvard

Ghofrani H., Simonneau G., D'Armini A. M., Fedullo P., Howard L. S., Jaïs X., Jenkins D. P., Jing Z., Madani M. M., Martin N., Mayer E., Papadakis K., Richard D. and Kim N. H. (20180605). Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. : The Lancet. Respiratory medicine.

MLA

Ghofrani Hossein-Ardeschir, Simonneau Gérald, D'Armini Andrea M, Fedullo Peter, Howard Luke S, Jaïs Xavier, Jenkins David P, Jing Zhi-Cheng, Madani Michael M, Martin Nicolas, Mayer Eckhard, Papadakis Kelly, Richard Dominik and Kim Nick H. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. : The Lancet. Respiratory medicine. 20180605.